Press release
Lawsuit filed for Investors in shares of BELLUS Health Inc. (NASDAQ: BLU)
A lawsuit was filed on behalf of investors in BELLUS Health Inc. (NASDAQ: BLU) shares over alleged securities laws violations.
Investors who purchased shares of BELLUS Health Inc. (NASDAQ: BLU) have certain options and for certain investors are short and strict deadlines running. Deadline: May 17, 2021. NASDAQ: BLU investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Canada based BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders.
BELLUS Health Inc’s lead product is BLU-5937, which is being developed for the treatment of chronic cough (one that lasts over eight weeks) and other afferent hypersensitization-related disorders.
On July 6, 2020, BELLUS Health Inc. provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough. Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.
The plaintiff claims that between September 5, 2019 and July 5, 2020, the defendants made false and/or misleading statements and/or failed to disclose information that resulted in a scheme that deceived the investing public regarding BELLUS Health Inc. 's business, operations, drug products, drug product development, competition, and present and future business prospects, that facilitated the Company's September 2019 public offering ("Offering"), that created artificial demand for the BELLUS Health Inc. common shares sold in the Offering, that enabled the Company to receive approximately $70 million in net proceeds from the sale of BELLUS Health Inc. common stock in the Offering, and that caused purchases of BELLUS Health Inc. publicly traded common stock at artificially inflated prices.
Those who purchased shares of BELLUS Health Inc. (NASDAQ: BLU) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in shares of BELLUS Health Inc. (NASDAQ: BLU) here
News-ID: 2260178 • Views: …
More Releases from Shareholders Foundation
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd.
Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
More Releases for BELLUS
U.S. Microneedling Market New Product Development & Latest Trends | Revance Ther …
"The U.S. Microneedling Market Size is projected to reach at a CAGR of 8.5% during 2025-2034."
U.S. Microneedling market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the U.S. Microneedling Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry…
Bellus All Natural Labs Wins Prestigious 2024 Corporate Excellence Magazine Awar …
Corporate Vision Magazine recognizes Bellus for product formulation and private label cosmetic achievements
POMPTON PLAINS, NJ - Sep 5, 2024 - Bellus All Natural Labs, the U.S. leader in private label and custom health and beauty (H&B) formulations, today announced it has received the 2024 Corporate Excellence Award from Corporate Vision Magazine for "Best Private Label Skincare and Custom Formulation Company." Bellus is a formulation services contract manufacturer of private label…
Dermabrasion and Microneedling Market to Witness Huge Growth by Key Players: Med …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Dermabrasion and Microneedling industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Dermabrasion and Microneedling market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Dermabrasion and Microneedling report includes a…
Investigation announced for Long-Term Investors in BELLUS Health Inc. (NASDAQ: B …
An investigation on behalf of current long-term investors in shares of BELLUS Health Inc. (NASDAQ: BLU) concerning potential breaches of fiduciary duties by certain directors and officers of BELLUS Health Inc. was announced.
Investors who are current long term investors in BELLUS Health Inc. (NASDAQ: BLU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
Deadline on May 17th coming up in Lawsuit for Investors in BELLUS Health Inc. (N …
A deadline is coming up on May 17, 2021 in the lawsuit filed for certain investors of BELLUS Health Inc. (NASDAQ: BLU) over alleged securities laws violations by BELLUS Health Inc.
Investors who purchased shares of BELLUS Health Inc. (NASDAQ: BLU) have certain options and there are strict and short deadlines running. Deadline: May 17, 2021. NASDAQ: BLU stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Sarcoidosis Drug Market : By Relief therapeutics holding SA, Firststring researc …
Sarcoidosis Drug Market Report examines the competitive scenario and gives all major players market share based on production capacity, sales, revenues, geographical presence and other important factors. The report includes a detailed description, a competitive scenario, a wide range of market leaders and business strategies adopted by competitors together with their SWOT analysis. It also provides explicit information about fusions, acquisitions, joint ventures and other important market activities in recent years.…
